| Previous Close | 5.34 |
| Open | 5.42 |
| Day High | 5.59 |
| Day Low | 5.35 |
| 52-Week High | 13.88 |
| 52-Week Low | 4.45 |
| Volume | 2.57M |
| Average Volume | 4.05M |
| Market Cap | 840.05M |
| PE | -54 |
| EPS | -0.1 |
| Moving Average 50 Days | 5.63 |
| Moving Average 200 Days | 8.27 |
| Change | 0.06 |
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed dr
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
GlobeNewswire Inc.
Jan 29, 2026 1:30 PM GMT
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open
Certara Appoints Jon Resnick as Chief Executive Officer
GlobeNewswire Inc.
Dec 11, 2025 11:00 AM GMT
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa